UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
about
Sulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusInterventions for latent autoimmune diabetes (LADA) in adultsPostprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 DiabetesType 2 diabetes: etiology and reversibilityGPR119 agonists for the treatment of type 2 diabetesChronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cellsWhy treatment fails in type 2 diabetesThe characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional studyGlucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.Defining and characterizing the progression of type 2 diabetes.Kir6.2 E23K polymorphism is related to secondary failure of sulfonylureas in non-obese patients with type 2 diabetes.Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT studyExenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.Adipsin is an adipokine that improves β cell function in diabetes.Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment.Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes.Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysisPharmacogenetics of Anti-Diabetes Drugs.In vivo pancreatic β-cell-specific expression of antiaging gene Klotho: a novel approach for preserving β-cells in type 2 diabetesSGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetesDapagliflozin for the treatment of type 2 diabetes: a review of the literatureEvaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function.Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.Mitochondrial dysfunction and β-cell failure in type 2 diabetes mellitus.A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.Importance of Beta Cell Function for the Treatment of Type 2 DiabetesPharmacological treatment of type 2 diabetes.Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth studySurface plasmon resonance reveals a different pattern of proinsulin autoantibodies concentration and affinity in diabetic patients.Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY studyRosiglitazone RECORD study: glucose control outcomes at 18 months.The management of type 2 diabetes mellitus in children and adolescents.Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus.Youth type 2 diabetes: insulin resistance, beta-cell failure, or both?Factors associated with no apparent coronary artery disease in patients with type 2 diabetes mellitus for more than 10 years of duration: a case control study.Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.Achieving fasting and postprandial blood glucose control in type 2 diabetes.
P2860
Q24186660-C49BFC09-76CA-4331-A31F-9B7B7B92404AQ24197884-0AEDB265-0512-4533-9438-7A918885EEB3Q24244270-D9B9B38B-4CCE-4D55-AB07-64A76295A5FFQ26747696-930B39E9-3753-451C-A057-88E0F22BB2CAQ27016644-0C29C484-F8E8-42E9-8956-A5A86D71BD2FQ28259606-950208BD-1F68-4502-806E-82D45F63D82BQ28473974-CC4036DE-8FBE-4D99-8140-2E9942F083D7Q33380396-DBEAA862-B83C-417A-AA4E-08260AD9BF4EQ33577817-01DCC909-623C-437B-96A9-3868762EBC78Q33585850-DC63104A-3E1A-4998-B388-F102CD137388Q33610728-28BB517F-B9E5-4E09-B0D7-29EEC926182DQ33628244-7FEB0BA8-F1A5-4515-8F75-EA6FB90C2BD0Q33686766-A875A17D-78E9-4F47-8F9D-28A8B81CDB72Q33884913-E39790B7-1145-48BC-B68A-6217946C4617Q34025740-18892F46-7434-4646-B77B-A78037658D96Q34128192-6704E13A-52BA-42BD-B990-861B15FA1E1CQ34131203-E65C9F58-6807-4775-B616-1A486669595EQ34142893-52E72D7C-A41E-42E7-95FF-EFBE336AD340Q34181995-DF72C078-E1CF-41A2-A1AE-7D16360B0BC2Q34446705-D9FCED71-B5A9-43C3-B892-58FE1D1F3FB3Q34460468-27C2D393-EABA-459D-BC71-CA824CAF31CEQ34710819-1A59CDC7-628C-4C48-8C7E-4588F6AEA5FCQ34727773-AEF434DA-12A3-46AD-9F0C-27564F4C9EEAQ35214435-567F608D-76CC-46E8-98B9-F546C5DB3F4DQ35225372-341CF952-BEDE-4603-BCCA-4DB1CAE72918Q35550591-149F4122-D6FC-4960-B1DB-313FAC85FC7EQ35643633-FB188FA8-C3E1-49E6-BB63-257F44AB2AB0Q35667116-051F06CB-3982-4282-A6A6-B74D7499D458Q35821479-901771C2-49A6-4273-BC08-848E2B2DE2D2Q35822130-DFAFF616-0C92-4AE0-9666-70EA2E32EE41Q35839894-C29CC796-DE1D-47B9-BA82-7163B214F285Q35893382-7099EC0E-6354-4EE3-B251-8E28D0BC80BEQ35968784-0C5640E6-E3CD-484A-BEBE-D63F52C5FFF0Q35987411-FB150A79-E9C3-4AC3-A680-D5A0D4CB28D7Q36063768-EF7396F8-C311-420E-BC62-66EB923A3495Q36131766-031CAF5C-8DBB-47C7-AFCF-B8289B524F4EQ36190631-F32A03B8-9D87-4586-81B7-8C806DB3A17FQ36235047-8799497E-53D2-4B47-8A8D-A508CE6953F7Q36366176-46F8F964-34F1-40A7-8A97-FA104E1722D9Q36636422-E489A8EF-18AA-4621-A65C-4BEAB61DF694
P2860
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
UKPDS 26: Sulphonylurea failur ...... Diabetes Study (UKPDS) Group.
@en
UKPDS 26: Sulphonylurea failur ...... UK Prospective Diabetes Study
@nl
type
label
UKPDS 26: Sulphonylurea failur ...... Diabetes Study (UKPDS) Group.
@en
UKPDS 26: Sulphonylurea failur ...... UK Prospective Diabetes Study
@nl
prefLabel
UKPDS 26: Sulphonylurea failur ...... Diabetes Study (UKPDS) Group.
@en
UKPDS 26: Sulphonylurea failur ...... UK Prospective Diabetes Study
@nl
P2093
P1433
P1476
UKPDS 26: Sulphonylurea failur ...... Diabetes Study (UKPDS) Group.
@en
P2093
D R Matthews
I M Stratton
R C Turner
R R Holman
P304
P356
10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.3.CO;2-N
P577
1998-04-01T00:00:00Z